EXPLANATORY STATEMENT
INSTRUMENT NUMBER PB 36 OF 2010
NATIONAL HEALTH ACT 1953
AMENDMENT DETERMINATION UNDER SECTION 84AF
Summary
This legislative instrument in giving effect to recommendations of the Pharmaceutical Benefits Advisory Committee (PBAC) amends the determination under section 84AF made by legislative instrument number PB 16 of 2010 which came into effect on 1 April 2010. The amendments provide for additions and changes to the responsible persons for the brands of pharmaceutical items. These persons are bodies corporate and are identified by their company name and Australian Business Number (ABN). The amendments are set out in the items of Schedule 1 to the instrument.
Purpose and operation
Part VII of the National Health Act 1953 (the Act) is the legislative basis of the Pharmaceutical Benefits Scheme (PBS) by which the Commonwealth provides reliable, timely, and affordable access to a wide range of medicines for all Australians.
Subsection 85(1) provides that benefits are to be provided by the Commonwealth in accordance with Part VII in respect of pharmaceutical benefits.
Drugs and medicinal preparations to which Part VII applies are declared by the Minister by legislative instrument to be so under subsection 85(2). These are listed drugs as defined in subsection 84(1). Part VII also applies to certain extemporaneously-prepared medicinal preparations as a result of declarations under paragraph 85(2)(b).
The Minister by legislative instrument can determine the form or forms of a listed drug by reference to strength, type of unit, size of unit or otherwise (subsection 85(3)); the manner of administration of the form of the listed drug so determined (subsection 85(5)); and a brand of the pharmaceutical item (defined in subsection 84(1)) that has the listed drug in that form with that manner of administration (subsection 85(6)). These determinations govern (except for certain extemporaneously-prepared pharmaceutical benefits) what constitutes the pharmaceutical benefit (defined in subsection 84(1)) under Part VII of the Act.
Section 84AF empowers the Minister to determine that a person is the responsible person for a brand of a pharmaceutical item. The Minister can do this if the person has notified the Minister that the person is or will be the supplier of the brand of the pharmaceutical item to wholesalers or, if not, to approved pharmacists directly. The brand must be a listed brand (defined in subsection 84(1) as a brand in relation to which a determination under subsection 85(6) is in force), and there can be no determination in force that any other person is the responsible person for the brand of the pharmaceutical item or of any other pharmaceutical item.
A responsible person for a brand of pharmaceutical item has various responsibilities or functions under the Act. These include those in relation to entering into price agreements under section 85AD, compliance with price disclosure requirements under Division 3B, and the requirement to supply certain brands of pharmaceutical item for a specified period under Division 3C.
This instrument determines the responsible persons for the brands of pharmaceutical items set out in Schedule 1 to the instrument. These persons are bodies corporate and are identified in Schedule 1 by their company name and Australian Business Number (ABN). The names of the responsible persons were notified before the commencement of section 84AF as permitted by subsection 84AF(2).
A provision-by-provision description of the instrument is contained in the Attachment.
This instrument, expressed to commence on 1 May 2010, was made on 1 April 2010.
Consultations
This instrument affects pharmaceutical companies with medicines listed on the PBS. In relation to the introduction of the responsible person measure, pharmaceutical companies have been consulted during both the policy development and implementation phases. This has occurred through meetings with both peak body organisations and individual companies. Information on this measure has been disseminated through peak industry bodies and during regular meetings with a Stakeholder Reference Group. Particular information on the Responsible Person provisions has been provided by letter to those companies to whom the provisions will apply. Under section 84AF the Minister may only determine a person to be the responsible person for a brand of a pharmaceutical item if the person has notified the Minister that the person is or will be the supplier of the brand of the pharmaceutical item. Each of the persons determined in the instrument to be responsible persons has given the required notification to the Minister.
The PBAC is an independent expert body established by section 100A which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits. PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC. When recommending the listing of a medicine on the PBS, the PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.
ATTACHMENT
Paragraph 1: provides that this instrument commences on 1 May 2010.
Paragraph 2: provides that Schedule 1 amends PB 16 of 2010.
Schedule 1: provides for the following amendments:
SCHEDULE 1
Additions
Listed Drug | Form | Brand | Responsible Person |
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids | Oral powder 400 g (EleCare LCP) | EleCare LCP | Abbott Australasia Pty Ltd |
Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, single dose units | Optive | Allergan Australia Pty Limited |
Clopidogrel | Tablet 75 mg (as hydrogen sulfate) | APO-Clopidogrel | Apotex Pty Ltd |
Clopidogrel | Tablet 75 mg (as hydrogen sulfate) | Chem mart Clopidogrel | Apotex Pty Ltd |
Clopidogrel | Tablet 75 mg (as hydrogen sulfate) | Terry White Chemists Clopidogrel | Apotex Pty Ltd |
Dasatinib | Tablet 100 mg | Sprycel | Bristol-Myers Squibb Australia Pty Ltd |
Fludarabine | Powder for I.V. injection containing fludarabine phosphate 50 mg | Farine | Willow Pharmaceuticals Pty Ltd |
Interferon Beta-1a | Solution for injection 132 micrograms in 1.5 mL multidose cartridge | Rebif 44 | Merck Serono Australia Pty Ltd |
Irinotecan | I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL | Tecan | Willow Pharmaceuticals Pty Ltd |
Irinotecan | I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL | Tecan | Willow Pharmaceuticals Pty Ltd |
Lacosamide | Tablet 50 mg | Vimpat | UCB Australia Proprietary Limited |
Lacosamide | Tablet 100 mg | Vimpat | UCB Australia Proprietary Limited |
Lacosamide | Tablets 100 mg, 14 | Vimpat | UCB Australia Proprietary Limited |
Lacosamide | Tablet 150 mg | Vimpat | UCB Australia Proprietary Limited |
Lacosamide | Tablets 150 mg, 14 | Vimpat | UCB Australia Proprietary Limited |
Lacosamide | Tablet 200 mg | Vimpat | UCB Australia Proprietary Limited |
Lansoprazole | Capsule 30 mg | APO-Lansoprazole | Apotex Pty Ltd |
Lansoprazole | Capsule 30 mg | Lanzopran | Ranbaxy Australia Pty Limited |
Levodopa with Carbidopa and Entacapone | Tablet 75 mg-18.75 mg-200 mg | Stalevo 75/18.75/200mg | Novartis Pharmaceuticals Australia Pty Limited |
Levodopa with Carbidopa and Entacapone | Tablet 125 mg-31.25 mg-200 mg | Stalevo 125/31.25/200mg | Novartis Pharmaceuticals Australia Pty Limited |
Metformin | Tablet containing metformin hydrochloride 850 mg | Metformin-GA | Genepharm Pty Ltd |
Pantoprazole | Tablet (enteric coated) | Pantoprazole-GA | Genepharm Pty Ltd |
Pantoprazole | Tablet (enteric coated) | Pantoprazole-GA | Genepharm Pty Ltd |
Paroxetine | Tablet 20 mg (as mesilate) | Pharmacor Paroxo 20 | Meditech Int. Pty Ltd |
Perindopril | Tablet containing perindopril erbumine 2 mg | Perindopril-GA | Genepharm Pty Ltd |
Perindopril | Tablet containing perindopril erbumine 4 mg | Perindopril-GA | Genepharm Pty Ltd |
Perindopril | Tablet containing perindopril erbumine 8 mg | Perindopril-GA | Genepharm Pty Ltd |
Pravastatin | Tablet containing pravastatin sodium 40 mg | Pravastatin Sandoz | Sandoz Pty Ltd |
Simvastatin | Tablet 10 mg | Pharmacor Simvastatin 10 | Meditech Int. Pty Ltd |
Simvastatin | Tablet 20 mg | Pharmacor Simvastatin 20 | Meditech Int. Pty Ltd |
Simvastatin | Tablet 40 mg | Pharmacor Simvastatin 40 | Meditech Int. Pty Ltd |
Simvastatin | Tablet 80 mg | Pharmacor Simvastatin 80 | Meditech Int. Pty Ltd |
Terbinafine | Tablet 250 mg (as hydrochloride) | Terbix 250 | Meditech Int. Pty Ltd |
Deletions
Listed Drug | Form | Brand | Responsible Person |
Diazepam | Tablet 5 mg | Diazepam-DP | Genepharm Pty Ltd |
Fluoxetine | Capsule 20 mg (as hydrochloride) | Fluoxetine-DP | Genepharm Pty Ltd |
Pravastatin | Tablet containing pravastatin sodium 40 mg | Liprachol | Sandoz Pty Ltd |
Alteration of Forms and Brands
Listed Drug | Form | Brand | Responsible Person |
Amino acid formula with vitamins and minerals without lysine and low in tryptophan | From: Oral powder 400 g (XLYS, LOW TRY Analog) To: Oral powder 400 g (GA1 Anamix infant) | From: XLYS, LOW TRY Analog To: GA1 Anamix infant | Nutricia Australia Pty Limited |
Amino acid formula with vitamins and minerals without methionine | From: Oral powder 400 g (XMET Analog) To: Oral powder 400 g (HCU Anamix infant) | From: XMET Analog To: HCU Anamix infant | Nutricia Australia Pty Limited |
Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine | From: Oral powder 400 g (XMTVI Analog) To: Oral powder 400 g (MMA/PA Anamix infant) | From: XMTVI Analog To: MMA/PA Anamix infant | Nutricia Australia Pty Limited |
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine | From: Oral powder 400 g (Xphen, Tyr Analog) To: Oral powder 400 g (TYR Anamix infant) | From: Xphen, Tyr Analog To: TYR Anamix infant | Nutricia Australia Pty Limited |
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine | From: Oral powder 400 g (MSUD Analog) To: Oral powder 400 g (MSUD Anamix infant) | From: MSUD Analog To: MSUD Anamix infant | Nutricia Australia Pty Limited |
Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine | From: Oral powder 400 g (XP Analog LCP) To: Oral powder 400 g (PKU Anamix infant) | From: XP Analog LCP To: PKU Anamix infant | Nutricia Australia Pty Limited |
Alteration of Brands
Listed Drug | Form | Brand | Responsible Person |
Alprazolam | Tablet 250 micrograms | From: Zamhexal 0.25mg To: Alprazolam Sandoz | Sandoz Pty Ltd |
Ciprofloxacin | Tablet 750 mg (as hydrochloride) | From: Profloxin To: Ciprofloxacin Sandoz | Sandoz Pty Ltd |
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | From: Diclohexal To: Diclofenac Sandoz | Sandoz Pty Ltd |
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | From: Diclohexal To: Diclofenac Sandoz | Sandoz Pty Ltd |
Alteration of Responsible Person
Listed Drug | Form | Brand | Responsible Person |
Imipramine | Tablet containing imipramine hydrochloride 10 mg | Tolerade 10 | From: Aspen Pharmacare Australia Pty Limited To: PMIP Pty Ltd (this Responsible Person is identified as a corporation by the company name and the ACN number) |
Imipramine | Tablet containing imipramine hydrochloride 25 mg | Tolerade 25 | From: Aspen Pharmacare Australia Pty Limited To: PMIP Pty Ltd (this Responsible Person is identified as a corporation by the company name and the ACN number) |